This information barely touches the surface of how much influence Pharmaceutical Lobbyist and like interest have in our democratic process.
You always have to wonder who congress is really looking out for. Is it the people they represent as a governmental body, or is it the corporations that fund their election and reelection campaigns?
"AstraZeneca spent just under $2.4 million in lobbying expenses over the 12-month period ending July 1 on issues including the reverse payment bill."
"With Democrats in charge of both ends of Pennsylvania Avenue, this really ought to be a no-brainer: Should GlaxoSmithKline put a Democrat or a Republican in charge of its Washington lobbying shop? But, as obvious as the answer may be, the drug maker is wrestling with the choice — and it sheds light on what seems to be an industry-wide partisan disconnect. The in-house lobbying shops of at least eight of the nation’s largest drug companies are still run by Republicans, even as the industry’s major trade association, PhRMA, is desperately trying to cozy up to Democrats who now control both the Congress and the White House. It’s a point that has not been lost on Democrats on Capitol Hill. “They’re dealing with us the same way they dealt with us when we were in the minority, and we’re not,” said a Democratic House health staffer. “We literally don’t know where all the different companies stand on anything, so we just don’t care.” Beyond Glaxo, health policy insiders cite as another example of the industry’s blind spot Abbott Laboratories’ decision to hire a Republican to help lead the lobbying shop instead of promoting a well-respected Democrat. An Abbott spokeswoman declined comment. Merck, Bristol-Myers Squibb, Novartis, Pfizer, Eli Lilly, Genzyme and AstraZeneca also have Republicans heading their Washington lobbying shops, according to industry insiders.
See also Second stimulus? Never heard of it! Obama tiptoes into battle on earmarks Some women wanted more from W.H.
“It doesn’t make any sense,” a Democratic Senate health care aide said. “At the end of the day it hurts them, not us.” "
Lobbyists working for AstraZeneca Pharmaceuticals:
Lobbying Firm Hired
Subsidiary (Lobbied For)
Buckley, Richard E
Levinson, Kenneth I
Mott, Amanda Grashof
Olson, Richard Wayne
Rossin, Bradley Allen
Bryan Cave Strategies
Gould, James C
Henry, Denise M
Raffaelli, John D
Foley Hoag LLP
Guida Consulting Services
Guida, Alfonso V Jr
Johnson, Madigan et al
Murphy, Sheila J
Peck, Jeffrey J
Richardson, Sean J
Mehlman Vogel Castagnetti Inc
Brown, Jamie E
Finley Pickering, Elise
Mehlman, Bruce P
Thomas, David R
Stuntz, Davis & Staffier
Davis, Randall E
Tarplin, Downs & Young
Downs, Raissa H
Easton, Michelle P
Fordjour, Isaac A
Tarplin, Linda E
Young, Jennfier B
Williams & Jensen
Hart, Jack Steven
Olsen, George G
"The Congressional Black Caucus Foundation received $285,000 from Coca-Cola, $270,000 from the drug manufacturer AstraZeneca and $155,122 from Anheuser-Busch. In total, the Congressional Black Caucus and affiliated organizations got more than $1.5 million from companies.
AstraZeneca, which makes drugs like Crestor for high cholesterol and Nexium for heartburn, was also a top contributor to the Congressional Hispanic Caucus Institute, with a gift of $115,000.
Tony Jewell, a spokesman for AstraZeneca, said the contributions were a way of “building relationships and supporting worthwhile causes,” including efforts to improve the health of minorities and increase their participation in clinical trials."
"AstraZeneca fit that description, federal prosecutors say.
From 1993 to 1996, the London pharmaceutical company sent thousands of free samples of the prostate cancer drug Zolodex to doctors, knowing they would then fraudulently bill Medicare, Medicaid and other federally funded health care programs.
The company provided doctors free trips, educational grants and business assistance, according to the Justice Department, all to entice them to sell AstraZeneca's drugs, not their competitors'.
The company pleaded guilty in 2003 to a felony charge of health care fraud and agreed to pay $355 million in criminal and civil penalties.
That year, McCollum was hired by AstraZeneca as a Washington lobbyist.
Campbell making issue of situation
McCollum arranged a meeting between AstraZeneca and U.S. Rep. Mike Bilirakis, R-Tarpon Springs, related to legislation affecting an oral cancer drug AstraZeneca was hoping to sell, McCollum said Thursday.
That was the extent of the relationship, said McCollum. He lobbied for the company for less than a year, according to required federal filings, and his firm, Baker & Hostetler, was paid $60,000 for the work."
Now! Who do you trust?